Solventum Corporation $SOLV Holdings Reduced by Ananym Capital Management LP

Key Points

• Ananym Capital Management LP reduced its stake in Solventum Corporation by 37.7% during the first quarter, now holding approximately 6.3% of the company.
• Multiple institutional investors increased their positions in Solventum, with notable raises from Trian Fund Management (18.8%) and Independent Franchise Partners (263.1%) in recent quarters.
• Solventum reported $1.69 EPS for the last quarter, exceeding analyst expectations, and has set FY 2025 guidance between 5.800-5.950 EPS.

Ananym Capital Management LP lessened its holdings in Solventum Corporation (NYSE:SOLV - Free Report) by 37.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,077 shares of the company's stock after selling 100,646 shares during the period. Solventum comprises about 6.3% of Ananym Capital Management LP's portfolio, making the stock its 9th largest holding. Ananym Capital Management LP owned 0.10% of Solventum worth $12,628,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Trian Fund Management L.P. boosted its holdings in Solventum by 18.8% in the 4th quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock worth $559,054,000 after buying an additional 1,336,564 shares during the last quarter. Independent Franchise Partners LLP boosted its holdings in shares of Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company's stock worth $442,608,000 after purchasing an additional 4,217,570 shares during the last quarter. Davis Selected Advisers boosted its holdings in shares of Solventum by 0.8% during the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock worth $402,110,000 after purchasing an additional 41,524 shares during the last quarter. Boston Partners boosted its holdings in shares of Solventum by 101.3% during the 1st quarter. Boston Partners now owns 3,361,973 shares of the company's stock worth $255,554,000 after purchasing an additional 1,691,565 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Solventum by 3.3% during the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock worth $137,456,000 after purchasing an additional 58,373 shares during the last quarter.

Solventum Stock Down 0.7%

Solventum stock traded down $0.49 during mid-day trading on Wednesday, reaching $71.33. The company's stock had a trading volume of 804,348 shares, compared to its average volume of 1,320,374. The business's 50 day simple moving average is $73.70 and its 200 day simple moving average is $72.80. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The company has a market capitalization of $12.37 billion, a price-to-earnings ratio of 13.07, a price-to-earnings-growth ratio of 1.77 and a beta of 0.53. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion during the quarter, compared to analysts' expectations of $2.12 billion. During the same quarter last year, the company posted $1.56 EPS. Solventum's quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. KeyCorp began coverage on Solventum in a research report on Friday, June 6th. They issued a "sector weight" rating on the stock. Wall Street Zen raised shares of Solventum from a "buy" rating to a "strong-buy" rating in a report on Monday. Piper Sandler reissued an "overweight" rating and set a $94.00 price objective (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. Wells Fargo & Company lifted their target price on shares of Solventum from $75.00 to $79.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Finally, Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $85.75.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.